TY - JOUR
T1 - The expanding spectrum of neurological disorders of phosphoinositide metabolism
AU - Volpatti, Jonathan R.
AU - Al-Maawali, Almundher
AU - Smith, Lindsay
AU - Al-Hashim, Aqeela
AU - Brill, Julie A.
AU - Dowling, James J.
N1 - Funding Information:
This research was supported by the Canadian Institutes of Health Research (324830), Muscular Dystrophy Canada (387144), the Natural Sciences and Engineering Research Council of Canada and the National Institutes of Health (AR074006-02).
Publisher Copyright:
© 2019. Published by The Company of Biologists Ltd.
PY - 2019
Y1 - 2019
N2 - Phosphoinositides (PIPs) are a ubiquitous group of seven low-abundance phospholipids that play a crucial role in defining localized membrane properties and that regulate myriad cellular processes, including cytoskeletal remodeling, cell signaling cascades, ion channel activity and membrane traffic. PIP homeostasis is tightly regulated by numerous inositol kinases and phosphatases, which phosphorylate and dephosphorylate distinct PIP species. The importance of these phospholipids, and of the enzymes that regulate them, is increasingly being recognized, with the identification of human neurological disorders that are caused by mutations in PIP-modulating enzymes. Genetic disorders of PIP metabolism include forms of epilepsy, neurodegenerative disease, brain malformation syndromes, peripheral neuropathy and congenital myopathy. In this Review, we provide an overview of PIP function and regulation, delineate the disorders associated with mutations in genes that modulate or utilize PIPs, and discuss what is understood about gene function and disease pathogenesis as established through animal models of these diseases.
AB - Phosphoinositides (PIPs) are a ubiquitous group of seven low-abundance phospholipids that play a crucial role in defining localized membrane properties and that regulate myriad cellular processes, including cytoskeletal remodeling, cell signaling cascades, ion channel activity and membrane traffic. PIP homeostasis is tightly regulated by numerous inositol kinases and phosphatases, which phosphorylate and dephosphorylate distinct PIP species. The importance of these phospholipids, and of the enzymes that regulate them, is increasingly being recognized, with the identification of human neurological disorders that are caused by mutations in PIP-modulating enzymes. Genetic disorders of PIP metabolism include forms of epilepsy, neurodegenerative disease, brain malformation syndromes, peripheral neuropathy and congenital myopathy. In this Review, we provide an overview of PIP function and regulation, delineate the disorders associated with mutations in genes that modulate or utilize PIPs, and discuss what is understood about gene function and disease pathogenesis as established through animal models of these diseases.
KW - ALS
KW - Charcot Marie Tooth disease
KW - Congenital myopathy
KW - Neurogenetic
KW - Phosphoinositides
UR - http://www.scopus.com/inward/record.url?scp=85071281193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071281193&partnerID=8YFLogxK
U2 - 10.1242/dmm.038174
DO - 10.1242/dmm.038174
M3 - Article
C2 - 31413155
AN - SCOPUS:85071281193
SN - 1754-8403
VL - 12
JO - DMM Disease Models and Mechanisms
JF - DMM Disease Models and Mechanisms
IS - 8
M1 - dmm038174
ER -